SL-11047 in Treating Patients With Relapsed or Refractory Lymphoma

DISEASE CHARACTERISTICS: Histologically* confirmed Hodgkin's or non-Hodgkin's lymphoma (NHL) of any histology The following NHL types are eligible: Diffuse large B-cell lymphoma Follicular lymphoma Mantle Cell lymphoma Marginal zone lymphoma (including lymphoma of mucosa-associated tissue [MALT]) Anaplastic large cell lymphoma Peripheral T-cell lymphoma Cutaneous T-cell lymphoma T/NK cell lymphoma Angioimmunoblastic lymphadenopathy-type T-cell lymphoma Burkitt's lymphoma NOTE: * If histologic confirmation was made at initial diagnosis, confirmation of relapsed or refractory disease can be made by repeat histologic evaluation OR by evidence of regrowth at a site of disease that was previously histologically confirmed Relapsed after or refractory to ≥ 2 prior therapeutic regimens OR patient is ineligible to receive potentially curative therapy Bidimensionally measurable or evaluable (e.g., bone marrow or infiltrative organ involvement) disease by physical exam or radiographic study No suspicion or evidence of lymphomatous meningitis PATIENT CHARACTERISTICS: Life expectancy ≥ 12 weeks ECOG performance status 0-4 Not pregnant Negative pregnancy test Fertile patients must use medically prescribed contraception Absolute neutrophil count ≥ 1,000/mm^3* Platelet count ≥ 50,000/mm^3* Hemoglobin ≥ 8 g/dL* Serum creatinine ≤ 2.0 mg/dL Total bilirubin ≤ 2.0 mg/dL** Transaminases < 5 times upper limit of normal** No other malignancy within the past 5 years other than curatively treated non-metastatic skin cancer or in situ cervical carcinoma No history of significant or symptomatic cardiac arrhythmia No history of myocardial infarction No significant ventricular conduction abnormality by ECG or Holter monitoring, as evidenced by any of the following: Prior myocardial infarction Three or more premature ventricular contractions in a row No history of pancreatitis No history of recent gastrointestinal bleeding Must have heme-negative stool at enrollment NOTE: *Cytopenias due to direct lymphomatous involvement allowed NOTE: **Elevated due to direct lymphomatous involvement allowed PRIOR CONCURRENT THERAPY: See Disease Characteristics More than 3 weeks since prior chemotherapy Recovered from prior chemotherapy (alopecia or anemia allowed) More than 3 weeks since prior investigational drugs No prophylactic antiemetics during course 1 No other concurrent investigational drugs